IL250328B - Polymorphs of selinxor - Google Patents

Polymorphs of selinxor

Info

Publication number
IL250328B
IL250328B IL250328A IL25032817A IL250328B IL 250328 B IL250328 B IL 250328B IL 250328 A IL250328 A IL 250328A IL 25032817 A IL25032817 A IL 25032817A IL 250328 B IL250328 B IL 250328B
Authority
IL
Israel
Prior art keywords
selinexor
polymorphs
Prior art date
Application number
IL250328A
Other languages
English (en)
Hebrew (he)
Other versions
IL250328A0 (en
Original Assignee
Karyopharm Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karyopharm Therapeutics Inc filed Critical Karyopharm Therapeutics Inc
Publication of IL250328A0 publication Critical patent/IL250328A0/en
Publication of IL250328B publication Critical patent/IL250328B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL250328A 2014-08-15 2017-01-29 Polymorphs of selinxor IL250328B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462038069P 2014-08-15 2014-08-15
PCT/US2015/045395 WO2016025904A1 (en) 2014-08-15 2015-08-14 Polymorphs of selinexor

Publications (2)

Publication Number Publication Date
IL250328A0 IL250328A0 (en) 2017-03-30
IL250328B true IL250328B (en) 2022-05-01

Family

ID=53969460

Family Applications (1)

Application Number Title Priority Date Filing Date
IL250328A IL250328B (en) 2014-08-15 2017-01-29 Polymorphs of selinxor

Country Status (18)

Country Link
US (6) US10519139B2 (enExample)
EP (2) EP3180331B1 (enExample)
JP (3) JP6777626B2 (enExample)
KR (1) KR102608259B1 (enExample)
CN (3) CN111484483B (enExample)
AU (4) AU2015301484B2 (enExample)
CA (1) CA2957266A1 (enExample)
CO (1) CO2017001884A2 (enExample)
DK (1) DK3180331T3 (enExample)
EA (1) EA201790384A1 (enExample)
ES (1) ES2926377T3 (enExample)
IL (1) IL250328B (enExample)
MA (1) MA40254B1 (enExample)
MX (2) MX388170B (enExample)
SG (2) SG11201700789SA (enExample)
UA (1) UA123535C2 (enExample)
WO (1) WO2016025904A1 (enExample)
ZA (1) ZA201700880B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI574957B (zh) 2011-07-29 2017-03-21 佳佑製藥治療公司 含有醯肼的核運輸調控子及其用途
RS58058B1 (sr) 2012-05-09 2019-02-28 Biogen Ma Inc Modulatori nukleusnog transporta i njihove upotrebe
US10202366B2 (en) 2013-03-15 2019-02-12 Karyopharm Therapeutics Inc. Methods of promoting wound healing using CRM1 inhibitors
DK3010892T3 (en) 2013-06-21 2019-04-15 Karyopharm Therapeutics Inc 1,2,4-TRIAZOLES AS NUCLEAR TRANSPORT MODULATORS AND APPLICATIONS THEREOF
KR102608259B1 (ko) * 2014-08-15 2023-11-29 카리오팜 쎄라퓨틱스, 인코포레이티드 셀리넥소의 다형태
WO2017117535A1 (en) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
EP3397633A1 (en) 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
US11034675B2 (en) 2016-01-08 2021-06-15 Dr. Reddy's Laboratories Limited Solid forms of Selinexor and process for their preparation
US11602530B2 (en) 2016-11-28 2023-03-14 Biogen Ma Inc. CRM1 inhibitors for treating epilepsy
US10993943B2 (en) 2017-01-05 2021-05-04 Watson Laboratories Inc. Crystalline forms of selinexor and process for their preparation
CN106831731B (zh) * 2017-01-17 2019-11-08 广州市闻皓生物科技有限公司 一种Selinexor原料药的合成方法
WO2019232724A1 (en) 2018-06-06 2019-12-12 Xw Laboratories, Inc. Compounds as nuclear transport modulators and uses thereof
WO2020072008A1 (en) * 2018-10-04 2020-04-09 Deva Holding Anonim Sirketi Novel solid dispersions of selinexor
BR112021016762A2 (pt) * 2019-03-20 2021-10-19 Johnson Matthey Public Limited Company Cocristal de selinexor, composição farmacêutica, método de tratamento de doenças, e, processo para a preparação de cocristal de selinexor
MX2021013211A (es) * 2019-05-01 2022-03-11 Karyopharm Therapeutics Inc Proceso para la preparacion de inhibidores de xpo1 y productos intermedios para su uso en la preparacion de inhibidores de xpo1.
US20220218725A1 (en) * 2019-05-16 2022-07-14 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
EP3808742A1 (en) 2019-10-16 2021-04-21 Sandoz AG Polymorph of selinexor
WO2022087218A1 (en) 2020-10-21 2022-04-28 Karyopharm Therapeutics Inc. Crystalline form of selinexor
CN112679477B (zh) * 2020-12-17 2021-10-26 佛山奕安赛医药科技有限公司 塞利尼索及其中间体的制备方法
WO2023122014A1 (en) * 2021-12-20 2023-06-29 Raytheon Technologies Corporation Particle enhancement of ceramic matrix composites, method of manufacture thereof and articles comprising the same
CN116675677B (zh) * 2023-08-02 2023-09-26 中国林业科学研究院林产化学工业研究所 一种c8漆酚衍生物及其制备方法和应用

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1017398A (en) 1911-01-16 1912-02-13 John E Folsom Telegraph-key.
CS229934B2 (en) 1981-07-07 1984-07-16 Pfizer Production method subst.indolylacryte acid derivative
KR840000529A (ko) 1981-07-07 1984-02-25 콘스탄틴 루이스 클레멘트 인돌 유도체의 제조방법
US4778796A (en) 1985-07-19 1988-10-18 Dainippon Pharmaceutical Co., Ltd. ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same
IL97249A (en) 1990-02-23 1995-01-24 Takeda Chemical Industries Ltd Compounds of 7,6,5,4-tetrahydrothiazole] B-5,4 [pyridine and compounds of 5,6-dihydro-H4-pyrrolo] D-3,2 [thiazole, their manufacture, and pharmaceutical compositions including or
JP3111321B2 (ja) 1990-02-23 2000-11-20 武田薬品工業株式会社 縮合チアゾール化合物
US5541213A (en) 1993-06-24 1996-07-30 Eisai Co., Ltd. Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility
US5468353A (en) 1994-05-05 1995-11-21 Minnesota Mining And Manufacturing Company Mist suppressant for solvent extraction metal electrowinning
CN1088062C (zh) 1994-11-23 2002-07-24 纽罗根公司 某些4-氨基甲基-2-取代的咪唑衍生物2-氨基甲基-4-取代的咪唑衍生物新的一族多巴胺受体亚型特异性配体
US20030018025A1 (en) 1995-06-07 2003-01-23 Neurogen Corporation, Corporation Of The State Of Delaware Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands
JPH11513382A (ja) 1995-10-20 1999-11-16 ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング 5員複素環化合物、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法
EP1671966A1 (en) 1996-04-04 2006-06-21 Shionogi & Co., Ltd. Cephem compounds and pharmaceutical compositions containing the same
JP4054992B2 (ja) 1996-04-25 2008-03-05 日産化学工業株式会社 エチレン誘導体および有害生物防除剤
ATE244219T1 (de) 1996-04-25 2003-07-15 Nissan Chemical Ind Ltd Ethylenderivate und pestizide
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
US5994398A (en) 1996-12-11 1999-11-30 Elan Pharmaceuticals, Inc. Arylsulfonamides as phospholipase A2 inhibitors
JP4416198B2 (ja) 1997-12-19 2010-02-17 武田薬品工業株式会社 アニリド誘導体、その製造法および用途
WO1999050264A1 (en) 1998-03-30 1999-10-07 Kyowa Hakko Kogyo Co., Ltd. Quinazoline derivatives
US6743585B2 (en) 1999-09-16 2004-06-01 Agilent Technologies, Inc. Methods for preparing conjugates
AR029803A1 (es) 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
EP2083005A1 (en) 2000-09-29 2009-07-29 TopoTarget UK Limited Carbamic acid compounds comprising an amide linkage as HDAC inhibitors
CA2465978C (en) 2001-09-14 2015-04-07 Soon Hyung Woo Inhibitors of histone deacetylase
AU2003287965A1 (en) 2002-10-24 2004-05-13 Carex Sa Modulation of peroxisome proliferator activated receptors activity
DE10250743A1 (de) 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
JP4145230B2 (ja) 2002-11-01 2008-09-03 武田薬品工業株式会社 神経障害の予防・治療剤
ZA200503967B (en) * 2002-11-01 2006-11-29 Takeda Pharmaceutical Agent for preventing or treating neuropathy
US7342115B2 (en) 2002-11-08 2008-03-11 Neurogen Corporation 3-substituted-6-aryl pyridines
CA2512886A1 (en) 2003-02-28 2004-09-10 Galderma Research & Development, S.N.C. Ligands that modulate lxr-type receptors
US7667041B2 (en) 2004-05-26 2010-02-23 Eisai R&D Management Co., Ltd. Cinnamide compound
CN101014595A (zh) 2004-08-11 2007-08-08 杏林制药株式会社 新型环状氨基苯甲酸衍生物
WO2006019020A1 (ja) 2004-08-16 2006-02-23 Sankyo Company, Limited 置換されたウレア化合物
JPWO2006088246A1 (ja) 2005-02-18 2008-07-10 武田薬品工業株式会社 Gpr34受容体機能調節剤
TWI330639B (en) 2005-11-15 2010-09-21 Otsuka Pharma Co Ltd Oxazole compound and pharmaceutical composition
JP2007210929A (ja) 2006-02-09 2007-08-23 Sankyo Co Ltd ウレア化合物を含有する医薬
EA016464B1 (ru) 2006-03-09 2012-05-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Полициклические производные арилимидазола
JP5554988B2 (ja) 2006-04-07 2014-07-23 メチルジーン インコーポレイテッド ヒストンデアセチラーゼの阻害剤
JP5290749B2 (ja) 2006-04-18 2013-09-18 日本ケミファ株式会社 ペルオキシソーム増殖剤活性化受容体δの活性化剤
WO2007147336A1 (fr) 2006-06-13 2007-12-27 Shanghai Institue Of Materia Medica, Chinese Academy Of Sciences Composés non nucléosidiques hétérocycliques, leur préparation, compositions pharmaceutiques, et leur utilisation en tant qu'agents antiviraux
PL2054411T3 (pl) 2006-07-27 2015-02-27 Amorepacific Corp Nowe związki, ich izomery lub ich farmaceutycznie dopuszczalne sole jako antagoniści receptora waniloidowego oraz zawierające je kompozycje farmaceutyczne
EP2090570B1 (en) 2006-09-05 2011-11-09 Kyowa Hakko Kirin Co., Ltd. Imidazole derivative
EP1939180A1 (en) 2006-12-20 2008-07-02 sanofi-aventis Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
EP1942104A1 (en) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
US7795457B2 (en) 2007-02-26 2010-09-14 Kosan Biosciences Incorporated Carbamate compounds
EP2003118A1 (de) 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Zimtsäurederivate als Modulatoren des EP2-Rezeptors
TW201011003A (en) 2008-08-08 2010-03-16 Synta Pharmaceuticals Corp Triazole compounds that modulate HSP90 activity
AU2010271205A1 (en) 2009-07-09 2012-02-09 Moko Therapeutics Llc. Method of wound healing and scar modulation
US8518968B2 (en) 2009-12-04 2013-08-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hydrazone and diacyl hydrazine compounds and methods of use
CN103002742B (zh) 2010-03-05 2016-07-13 卡尔约药物治疗公司 核转运调节剂及其应用
CA2824808A1 (en) 2011-01-17 2012-07-26 Karyopharm Therapeutics, Inc. Olefin containing nuclear transport modulators and uses thereof
TWI574957B (zh) 2011-07-29 2017-03-21 佳佑製藥治療公司 含有醯肼的核運輸調控子及其用途
WO2013019561A1 (en) 2011-07-29 2013-02-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
WO2013020024A2 (en) 2011-08-03 2013-02-07 Karyopharm Therapeutics, Inc. Maleimide compounds and methods of treatment
RS58058B1 (sr) 2012-05-09 2019-02-28 Biogen Ma Inc Modulatori nukleusnog transporta i njihove upotrebe
US20160016916A1 (en) 2013-03-15 2016-01-21 Karyopharm Therapeutics Inc. Exo Olefin-Containing Nuclear Transport Modulators and Uses Thereof
US10202366B2 (en) * 2013-03-15 2019-02-12 Karyopharm Therapeutics Inc. Methods of promoting wound healing using CRM1 inhibitors
DK3010892T3 (en) 2013-06-21 2019-04-15 Karyopharm Therapeutics Inc 1,2,4-TRIAZOLES AS NUCLEAR TRANSPORT MODULATORS AND APPLICATIONS THEREOF
WO2014205393A1 (en) 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US11567063B2 (en) * 2013-11-15 2023-01-31 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods for assessing cell viability or predicting cell response to a treatment using cell movement
CN107209187B (zh) 2014-07-11 2021-04-20 国立健康与医学研究所 用于诊断血液癌症的方法
AU2015296322B2 (en) * 2014-07-26 2019-09-19 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as CDK inhibitors and uses thereof
KR102608259B1 (ko) 2014-08-15 2023-11-29 카리오팜 쎄라퓨틱스, 인코포레이티드 셀리넥소의 다형태
US10777299B2 (en) 2015-08-28 2020-09-15 The Trustees Of Columbia University In The City Of New York Systems and methods for matching oncology signatures
EP3397633A1 (en) 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
WO2017117535A1 (en) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US11034675B2 (en) * 2016-01-08 2021-06-15 Dr. Reddy's Laboratories Limited Solid forms of Selinexor and process for their preparation
JP6765198B2 (ja) 2016-03-10 2020-10-07 パナソニック株式会社 潜熱蓄熱材及びそれを用いる蓄熱システム
US11602530B2 (en) 2016-11-28 2023-03-14 Biogen Ma Inc. CRM1 inhibitors for treating epilepsy
US10993943B2 (en) * 2017-01-05 2021-05-04 Watson Laboratories Inc. Crystalline forms of selinexor and process for their preparation
CN106831731B (zh) 2017-01-17 2019-11-08 广州市闻皓生物科技有限公司 一种Selinexor原料药的合成方法
WO2020198606A1 (en) 2019-03-27 2020-10-01 Karyopharm Therapeutics Inc. Biomarkers for selinexor
EP3808742A1 (en) 2019-10-16 2021-04-21 Sandoz AG Polymorph of selinexor
WO2021111103A1 (en) 2019-12-06 2021-06-10 Bae Systems Plc Light source
WO2022087218A1 (en) 2020-10-21 2022-04-28 Karyopharm Therapeutics Inc. Crystalline form of selinexor

Also Published As

Publication number Publication date
EP3180331A1 (en) 2017-06-21
EA201790384A1 (ru) 2017-08-31
DK3180331T3 (da) 2022-09-12
AU2020203246A1 (en) 2020-06-04
MA40254B1 (fr) 2022-09-30
US11746102B2 (en) 2023-09-05
CN111481553A (zh) 2020-08-04
AU2015301484B2 (en) 2020-02-20
EP3180331B1 (en) 2022-06-08
CN111484483A (zh) 2020-08-04
UA123535C2 (uk) 2021-04-21
ZA201700880B (en) 2020-01-29
SG10201808624VA (en) 2018-11-29
NZ728850A (en) 2024-03-22
US10519139B2 (en) 2019-12-31
SG11201700789SA (en) 2017-02-27
EP4112615A1 (en) 2023-01-04
KR20170043561A (ko) 2017-04-21
AU2015301484A1 (en) 2017-03-02
CA2957266A1 (en) 2016-02-18
JP2017527549A (ja) 2017-09-21
KR102608259B1 (ko) 2023-11-29
US20180215733A1 (en) 2018-08-02
JP2023052622A (ja) 2023-04-11
ES2926377T3 (es) 2022-10-25
WO2016025904A1 (en) 2016-02-18
MX2021014128A (es) 2022-01-04
CN111484483B (zh) 2023-05-26
MA40254A (fr) 2021-05-19
AU2020203246B2 (en) 2021-09-16
AU2024202835A1 (en) 2024-05-23
US20200283419A1 (en) 2020-09-10
JP7558310B2 (ja) 2024-09-30
AU2021286266A1 (en) 2022-01-06
CN107072992B (zh) 2020-03-10
JP2020143144A (ja) 2020-09-10
MX388170B (es) 2025-03-19
US20220135545A1 (en) 2022-05-05
JP7218323B2 (ja) 2023-02-06
CN111481553B (zh) 2023-09-01
MX2017002013A (es) 2017-05-12
US11807629B2 (en) 2023-11-07
IL250328A0 (en) 2017-03-30
JP6777626B2 (ja) 2020-10-28
CO2017001884A2 (es) 2017-07-19
US11753401B2 (en) 2023-09-12
CN107072992A (zh) 2017-08-18
US20230242516A1 (en) 2023-08-03
AU2021286266B2 (en) 2024-02-01
US11078190B2 (en) 2021-08-03
US12371420B2 (en) 2025-07-29
US20230242517A1 (en) 2023-08-03
US20240208943A1 (en) 2024-06-27

Similar Documents

Publication Publication Date Title
IL273230A (en) Preparation of carbamoylpyridone-polycyclic compounds
ZA201700880B (en) Polymorphs of selinexor
HU4602U (en) Set of saggar assembly
SI3524234T1 (sl) Trdne oblike sofosbuvira
PL3113773T3 (pl) Krystaliczne postaci grapiprantu
IL246979A0 (en) Crystalline forms of sofosbuvir
ZA201706282B (en) Solid forms of menaquinols
HU4603U (en) Set of saggar assembly
IL265180B (en) New polymorphs and new solid states of tiacomycin b
ZA201608686B (en) Interseparation of metals
IL249130B (en) Preparation of piperidine-4-carbothioamide
GB2544217B (en) Chlorination of sucrose-6-esters
SI3253769T1 (sl) Novi polimorfi
GB201403438D0 (en) Polymorphs
TWM489811U (en) Structural improvement of tube
IL249332A0 (en) Crystalline forms of sofosbuvir
PL3137475T3 (pl) Oczyszczanie epidaunorubicyny
GB201416951D0 (en) Method of synthesis
GB201414267D0 (en) Chlorination of sucrose-6-esters
GB201418773D0 (en) Mechanism of action
GB201404705D0 (en) Theory of Conceptual art